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Background: The popular methods for evaluating the initial therapeutic effect (ITE) of noninvasive positive pressure
ventilation (NPPV) can only roughly reflect the therapeutic outcome of a patient’s ventilation because they are
subjective, invasive and time-delayed. In contrast, vibration response imaging (VRI) can monitor the function of a
patient’s ventilation over the NPPV therapy in a non-invasive manner. This study aimed to investigate the value of
VRI in evaluating the ITE of NPPV for patients with acute exacerbation of chronic obstructive pulmonary disease
(AECOPD).
Methods: Thirty-six AECOPD patients received VRI at three time points: before NPPV treatment (T1), at 15 min of
NPPV treatment (T2), and at 15 min after the end of NPPV treatment (T4). Blood gas analysis was also performed at
T1 and at 2 hours of NPPV treatment (T3). Thirty-nine healthy volunteers also received VRI at T1 and T2. VRI
examination at the time point T2 in either the patients or volunteers did not require any interruption of the
on-going NPPV. The clinical indices at each time point were compared between the two groups. Moreover,
correlations between the PaCO2 changes (T3 vs T1) and abnormal VRI scores (AVRIS) changes (T2 vs T1) were
analyzed.
Results: No significant AVRIS differences were found between T1 and T2 in the healthy controls (8.51 ± 3.36 vs.
8.53 ± 3.57, P > 0.05). The AVRIS, dynamic score, MEF score and EVP score showed a significant decrease in AECOPD
patients at T2 compared with T1 (P < 0.05), but a significant increase at T4 compared with T2 (P < 0.05). We also
found a positive correlation (R2 = 0.6399) between the PaCO2 changes (T3 vs T1) and AVRIS changes (T2 vs T1).
Conclusions: VRI is a promising noninvasive tool for evaluating the initial therapeutic effects of NPPV in AECOPD
patients and predicting the success of NPPV in the early stage.
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Noninvasive positive pressure ventilation (NPPV) has be-
come a standard treatment for acute exacerbation of
chronic obstructive pulmonary disease (AECOPD) with a
success rate of 80%–85% [1-3]. Proper acknowledgement
of its indications is the key to a successful NPPV. How-
ever, consensus on indications for NPPV has not been
reached so far, and methods for predicting the success
rate of NPPV are still lacking [4]. As such, a dynamic
decision-making strategy is usually adopted in clinical
practice to predict the outcome of NPPV. For instance,
NPPV treatment can be tentatively carried out for several
hours before a decision can be made on whether it is to
be continued or certain NPPV parameters are to be ad-
justed according to the initial therapeutic effect (ITE). In
this regard, ITE is mainly evaluated based on the patient’s
clinical picture, such as improvement in dyspnea, vital
signs and blood gas analysis [5]. While these clinical ob-
servations may reflect the outcome of a patient’s ventila-
tion at hours later, some of them are readily affected by
other factors (for example, heart rate and respiratory
rate may be affected by fever or emotional stress). Due
to its subjective and patient-perceived nature, alleviation
of dyspnea may not always be accurate in assessing the
ITE. Blood gas analysis is considered more as the “gold
standard” but it is time-delayed and invasive. Therefore,
these clinical indexes are not optimal indicators or pre-
dictors for initial therapeutic effect and ultimately, for
the success of NPPV.
Vibration response imaging (VRI) is a non-invasive,
non-radioactive bedside imaging technique. VRI enables
respiratory sounds to be recorded and quantified object-
ively, and displayed in two-dimension images with the
help of a computer to show the changes in dynamic vi-
bration energy that generates respiratory sounds (lung
sounds) in a respiratory cycle. Therefore, VRI can track
continuous changes [6-8] of lung sounds during respira-
tory cycles, and may potentially allow for a quick display
of functional changes in a patient on NPPV. Theoretic-
ally, evaluation of ITE by using VRI can be more object-
ive and may yield better prediction of a successful NPPV.
Little is known so far about the possible role of VRI for
these purposes in clinical settings. In this study we com-
pared the VRI indices between healthy volunteers and
patients with AECOPD at different NPPV stages, in an
effort to explore whether VRI can be used to evaluate the
ITE of NPPV in patients with AECOPD and conse-
quently predict the success of NPPV.Subjects and methods
Subjects
This research was done in accordance with the Helsinki
Declaration and approved by the Ethical Committee ofthe First Affiliated Hospital to China Medical University.
Informed consents were obtained from all subjects.
Volunteers
Inclusion criteria for healthy volunteers were: absence of
chronic respiratory disease or cardiovascular disease,
negative history of respiratory infection in the previous
month, no smoking history, pulmonary function FEV1/
FVC >75%, FEV1% >80% and FVC% >80%. Exclusion
criteria were: severe deformity of thorax or spinal col-
umn, hypertrichosis, skin injury on the back, gestation
or lactation, implanted pacemaker or defibrillator. A
total of 39 healthy volunteers were selected, with a male
to female ratio of 2:1, a mean age of 36.5 ± 13.2 years, a
mean height of 1.64 ± 0.08 meters, a mean weight of
67.4 ± 10.9 kg, a mean FEV1% of 98.72 ± 5.34%, and a
mean FEV1/FVC of 86.21 ± 6.75%.
Patients
Inclusion criteria for AECOPD patients were: (1) a
change in baseline dyspnea, cough and/or sputum pro-
duction exceeding the normal range, showing an acute
exacerbation and requiring a change in previously used
drugs according to 2007 Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guideline [9]; (2)
patients diagnosed with type II respiratory failure with
PH >7.20; (3) patients who had not received NPPV ther-
apy before; (3) patients who met the basic requirements
for NPPV therapy [10], i.e. conscious mind (Kelly-
Matthay Score ≤ 3), good compliance, cooperative and
comprehensive abilities, little secretion or intact inde-
pendent cough and expectoration, and relatively stable
hemodynamics, and so on. Exclusion criteria were (1)
absolute contraindications for noninvasive ventilation
[10], including high risk of aspiration and weak airway
protective ability, cardiac and respiratory arrest, trauma,
burns, physical deformity, or recent surgery on the face
or neck or in the oropharyngeal cavity, and obstruction
of upper respiratory tract; (2) relative contraindications
for noninvasive ventilation [10], including failure to co-
operate with NPPV, severe hypoxemia, dysfunction of
extrapulmonary visceral organs, intestinal obstruction,
and recent operation to the esophagus or epigastrium;
(3) patients who refused to receive NPPV therapy; (4)
difficulty in V-array sensor placement, such as severe de-
formity of the thorax or spinal column, polytrichosis, skin
lesions on the back, gestation or lactation, implanted
pacemaker or defibrillator; (5) failure to receive a VRI
examination for at least three times and failure to toler-
ate NPPV for at least two hours. Finally, 36 patients with
AECOPD were recruited from the Respiratory Depart-
ment and ICU of the Emergency Department, including
19 smokers. Of these patients, the mean smoking index
(pack-years) was 24.31 ± 11.52, male to female ratio 2:1,
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meters and mean body-weight 61.5 ± 13.5 kg, respectively.
The mean duration of COPD and hospitalization for
AECOPD in the previous year was 23.63 ± 13.48 years
and 1.93 ± 0.74 times. The mean APACH II score was
16.48 ± 5.24. Lung auscultation identified moist rales in
21 patients and dry rales in 16. The chest X-ray was ab-
normal in 26 patients (pleural effusion or pulmonary
consolidation), including 10 cases of multi-lobular or
multi-segmental involvement.
Experimental procedures
(1) Subjects were recruited according to the inclusion
and exclusion criteria after giving their informed con-
sents. (2) They were inquired about their medical and
smoking histories and given physical check-up of the
chest. (3) Healthy volunteers completed a pulmonary
function test and the first VRI examination (T1) while
patients with AECOPD completed the first VRI examin-
ation and had their vital signs recorded. The comfort
level of respiration was assessed by the visual analogue
scale (VAS) in the patients [11]; the degree of dyspnea
was assessed by the scale for accessory muscle use
(SAMU) [12]. Moreover, blood gas analyses were also
performed. (4) All subjects received adaptive NPPV
treatment for 15 min, and then a second VRI examin-
ation was done at 15 min of NPPV treatment (T2). VRI
examination at the time point T2 in either the patients
or volunteers did not require any interruption of the on-
going NPPV. The vital signs, VAS and SAMU scores
were recorded in the AECOPD patients. (5) Healthy
volunteers completed the experiment while the patients
with AECOPD continued the NPPV treatment. The
above clinical indices in the AECOPD patients were de-
termined again at 2 hours of NPPV treatment (T3). The
blood gas analysis was also performed. (6) NPPV treat-
ment was paused at 2 hours from the start, then a third
VRI examination was performed, and the clinical indices
were determined at 15 min after the end of NPPV treat-
ment (T4). (7) Based on clinical outcomes, a decision
was made on whether the NPPV treatment was to be
continued or stopped for an individual AECOPD patient
(See Table 1).
Equipment and operation
A noninvasive ventilator (Vision, Philips Respironic,
USA) was used for NPPV treatment. The ventilator was
set in S/T mode with a 10 cmH2O inspiratory pressure,
a 5 cmH2O expiratory pressure and a 10 cpm backup re-
spiratory rate. The inhaled oxygen concentration in the
AECOPD patients was adjusted according to clinical
treatment needs (SpO2 ≥ 90%). After the AECOPD pa-
tients had received initial and adaptive NPPV treatment
for 15 min, the pressure level was increased graduallyuntil “the highest inspiratory pressure a patient can en-
dure” was reached after the VRI examination [10]. The
VRIXP System (Deep Breeze, Israel, Or-Akiva) was used
for VRI examination [13]. The subjects were instructed
to breathe naturally by mouth, and their pulmonary
sound vibration was recorded during the first 12 s. The
signals were analyzed systematically and the data were
processed.
Image analysis
The output data were presented with grayscale image
according to the relative strengths of breath sounds (see
Figure 1). Based on different intensities of vibration en-
ergy, the representative colors of high data field, low
data field and minimum data field are dark color (black),
light color (light grey) and white, respectively. The gray-
scale image, also defined as dynamic vibration energy
figure, consists of 71 frames accounting for data in 12 sec-
onds as a whole (each frame contains data in 0.17 sec-
onds). Furthermore, we divided the bilateral lungs into
6 areas, i.e. upper, middle and lower areas on each side.
The output of this system contains quantitative lung
data (QLD) of these areas in total vibration energy and
the vibrational energy curve represented the mean vi-
bration energy that varies with time. The maximal en-
ergy frame (MEF) was the frame when the vibration
energy reach peak in inspiratory phase. The dry and
moist rales could be detected automatically by means
of VRI, and marked by red and blue dots in the vibra-
tion energy figure correspondingly.
Analysis of the VRI images was performed to check
for the following aspects: (1) the vibrational energy
curve; (2) Dynamic image (observation from first frame
to the last frame one by one); (3) the shape of MEF
image; (4) QLD change in different areas; (5) dry and
moist rales; (6) Expiratory Vibration energy Peak (EVP),
for which we focused our observation on EVP synchro-
nization (ie temporal synchronization of EVP between
bilateral lungs) and EVP difference (ie amplitude differ-
ence of EVP between bilateral lungs).
Image scores
Using modified image analysis methods [13-15], three
clinicians who had received a systematic training on VRI
conducted a blinded image analysis independently. The
evaluators had not been informed about the subject’s in-
formation, the time points of image acquisition, or the
evaluations given by other evaluators. Abnormal VRI
image scores (AVRIS) were calculated by adding up the
sub-scores as follows (29 points in total): (1) Vibrational
energy curve (VEC) score (8 points), including the fol-
lowing abnormal signs (1 point for each sign): unsmooth,
inspiratory steep, spike, sag, plateau, single-peak, step
(expiratory phase peak value exceeding that of
Table 1 Experiment flow chart














√ √ Expiratory pressure
5 cmH2O
Pulmonary function √ Backup rate
10 times/minFirst VRI examination √ √
Vital signs √
Clinical score √
Blood gas analysis √
at 15 min of NPPV Vital signs √
treatment (T2) Clinical score √
VRI examination √ √
at 2 hours of NPPV Vital signs √ Increase the pressure
level in the principle of
“the highest inspiratory
pressure that a patient
can endure”
treatment (T3) Clinical score √
Blood gas analysis √
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lower and flat. (2) Dynamic image score (10 points).
Image jumping, including a non-vibration type (0 point,
the energy center has no quick changing and discontinu-
ous movement), a slight type (1 point, movement of theFigure 1 Typical VRI Image of an AECOPD before, during and stop NP
Panel A (T1), B (T2) and C(T4) represent the MEF (upper row), EVP (middle r
respectively. The VRI indices during treatment (such as MEF, EVP and QLD)
however, after stop NPPV treatment, these indices partly recovered. Abbrev
treatment, T4 = at 15 min after the end of NPPV treatment, MEF = maxima
QLD = Quantitative lung data.energy occurs in 1–2 frames occasionally at the inspira-
tory phase and the expiratory phase), a moderate type (2
points, the movement occurs at the inspiratory phase or
the expiratory phase), and a severe type (3 points, the
movement occurs at both the inspiratory phase and thePV treatment. The typical VRI image changes with NPPV treatment.
ow) and QLD (lower row) characteristics at the T1,T2 and T4 stages,
improved dramatically compared with those before treatment;
iations: T1 = Before NPPV treatment, T2 = at 15 min of NPPV
l energy frame Image, EVP = Expiratory vibration energy peak,
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dynamic image disorder, desynchronized development,
lag, inverse dominance, air trapping, and pneumatocele
at the inspiratory phase and the expiratory phase, was
scored 1 point. (3) Maximal energy frame (MEF) score (6
points). 0 point is for good MEF image shape, 1 point for
average MEF image shape, and 2 points for poor MEF
image shape. Each of the abnormal signs, including
unsmoothness, midline bending, defect and pneumato-
cele, was scored 1 point. (4) Rales (2 points). The dry and
moist rales were recorded separately, namely, no (0
point) and yes (1 point). (5) Expiratory Vibration energy
Peak (EVP). It was scored as per synchronization degree
of the left and right curves and amplitude heights (0
point was for synchronization, 1 point for desynchroni-
zation at the inspiratory phase or the expiratory phase
only, and 2 points for desynchronization at both the in-
spiratory phase and the expiratory phase. 0 point was for
the same amplitude height, and 1 point for the inconfor-
mity. The scoring was totally 3 points.)
Statistics analysis
The software SPSS13.0 was used for statistical analysis.
First, inter-evaluator repeatability was tested using intra-
class correlation coefficient (ICC). Categorical variables
were obtained by Chi-square test or Fisher Exact Prob-
ability Test. The VRI scores of the two groups at each
time point were tested using two-sample t-test, and
those between different time points in each group were
compared using paired t-test or one-way repeated mea-
surements ANOVA. Moreover, Pearson correlation coef-
ficient was used to investigate the relationship between
PaCO2 changes and AVRIS changes before and after
NPPV. A P value less than 0.05 was considered statisti-
cally significant.
Results
The reliability of VRI examination
Thirty-nine healthy volunteers and 36 AECOPD patients
successfully underwent a total of 410 VRI examinations
without any adverse events. Each examination lasted less
than 3 min. VRI records were not influenced by noise
from the ward or by the NPPV treatment. ICC showedTable 2 VRI image characteristics in healthy volunteers befor
TP VCG DIG MEFG
T1 1.67 ± 0.78 4.36 ± 1.78 0.74 ± 0.21
T2 2.07 ± 0.98 4.87 ± 1.91 0.76 ± 0.18
t 4.55 1.68 0.12
P 0.04 a 0.20 0.73
a Significant differences between T1 and T2.
Abbreviation: TP = Time point, T1 = Before NPPV treatment, T2 = 15 min NPPV trea
MEFG = Grading of maximal energy frame image, EVPG = Grading of expiratory vib
QLDD = The QLD changes between the right and left lungs.higher repeatability in the AVRIS between the three eva-
luators (ICC = 0.935, P < 0.05).
VRI image characteristics of healthy volunteers
The curve of vibration energy was smooth and con-
tinuous. Imaging of the two lungs was processed simul-
taneously and the dynamic images were developed
synchronously. Bean-shaped MEF displayed smooth,
continuous and complete edges and no defect. The sizes
and densities of bilateral lungs were roughly equal. The
mean total AVRIS was 8.51 ± 3.35 at T1 and 8.53 ± 3.5 at
T2, which showed no significant difference between the
2 time points (See Table 2, Figure 2).
Image characteristics of AECOPD patients
Before NPPV treatment (T1), the VEC was not so
smooth, showing step, plateau, sag curve and low and
flat expiratory phase curve. The dynamic image was
characterized by low imaging synchronization between
the left and right lungs, distinct image jumping, nu-
merous dry and moist rales, and unsmooth MEF edges
with turgor and defect, with a mean total AVRIS of
18.13 ± 3.67. At 15 min of NPPV treatment (T2), mean
total AVRIS (13.16 ± 3.67) was significantly lowered as
compared with T1. Sub-scores of AVRIS, such as dy-
namic score, MEF score and EVP curve score, were sig-
nificantly lower than those before NPPV treatment (T1)
(P < 0.05). The individual change of AVRIS declined in
most patients, mainly manifested by plateau, sagging,
image jumping and lagging, inverse dominance, synchro-
nicity and equal heights of EVP curves and smoothness
of MEF edges. However, the scores of a few patients
were increased, as reflected by respiratory creep curve,
plateau, low and flat expiratory phase, etc.. At 15 min
after the end of NPPV treatment (T4), mean total AVRIS
of 15.25 ± 1.26 was increased compared with that at T2.
Sub-items of AVRIS such as dynamic score, MEF score,
EVP curve score were significantly increased at T4 com-
pared with those at T2 (P < 0.05). the individual change
of AVRIS increased in most patients, mainly with mani-
festation of image jumping, lagging, inverse dominance,
synchronicity and equal heights of EVP curves, and
smoothness of MEF edge. However, the scores of somee and after NPPV treatment
EVPG RG AVRIS QLDD
1.15 ± 0.69 0.37 ± 0.15 8.51 ± 3.36 9.74 ± 4.53
1.23 ± 0.58 0.33 ± 0.15 8.53 ± 3.57 9.33 ± 7.65
0.36 0.44 0.05 0.71
0.55 0.52 0.82 0.41
tment, VCG = Grading of vibration curve, DIG = Grading of dynamic image,
ration energy peak, RG = Grading of rales, AVRIS = Abnormal VRI score,
Figure 2 Individual changes of VRI image score during and at the end of NPPV treatment. 1 Similarity: The similarity of vibrational energy
curve (VEC) among respiratory cycles. 2 Inspiratory steep: Steep peak in VEC caused by sudden increased energy during inspiratory phase. 3
Plateau: Platform in VED, representing little change in vibrational energy. 4 Sag: Concave segment in VED. 5 Low and flat expiration (LFE): low and
flat segment in VED during expiration phase. 6 Unsmooth edge of MEF image. 7 Midline bending of MEF image. 8 MEF image defect: abnormal
decreased or absent gray-scale intensity in MEF image. 9 Pneumatocele: abnormal increased gray-scale intensity in MEF image. 10 Image
jumping: rapid and discontinuous shift of the energy center in dynamic VRI. 11 Occurrence and development disorder: abnormal evolution of the
dynamic VRI. In normal subjects, the dynamic VRI appears from upper medial to lower lateral, and disappears from lower lateral to upper medial.
12 Asynchronization: the evolution of bilateral lungs is asynchronous in dynamic VRI. 13 Lag: the dynamic changes of VRI in one lung falls behind
another one). 14 Inverse dominance: the dominant side of VRI intensity inverted when breathing cycle changes from inspiratory phase to
expiratory phase. 15 Pneumatocele at inspiratory phase: abnormal increased gray-scale intensity in MEF image at inspiratory phase. 16
Pneumatocele at expiratory phase: abnormal increased gray-scale intensity in MEF image at expiratory phase. 17 EVP synchronization: temporal
synchronization of EVP between bilateral lungs. 18 EVP difference: amplitude difference of EVP between bilateral lungs.
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spiratory creep curve and the low and flat expiratory
phase curve.. The QLD differences between the right
and left lungs at T1 (0.34 ± 37.44) were significantly
lower than those at T2 (4.11 ± 32.61). The QLD differ-
ences at T4 (2.89 ± 35.45) was significantly lower than
that at T2 (See Table 3, Figures 1 and 2).
Clinical improvement in patients with AECOPD
The heart rate, respiration rate, VAS score and SAMU
scores at T2 were significantly lower than those at T1Table 3 VRI image characteristics in AECOPD patients before
TP VCG DIG MEFG E
T1 3.08 ± 0.92 7.75 ± 1.65 4.21 ± 1.25 2
T2 2.75 ± 1.15 5.83 ± 2.39 2.88 ± 1.59 1
T4 2.78 ± 0.51 6.51 ± 0.58 4.25 ± 0.85 1
F 1.39 5.64 5.76 5
P 0.26 <0.01 a, b c <0.01 a,b <
Post hoc: a P< 0.05 (T2 vs. T1); b P< 0.05 (T4 vs. T2), c P< 0.05 (T4 vs.T1).
Abbreviation: TP = Time point, T1 = Before NPPV treatment, T2 = at 15 min of NPPV
of vibration curve, DI Score = Grading of dynamic image, MEF Score = Score of max
RG = Grading of rales, AVRIS = Abnormal VRI score, QLDD = The QLD changes betw(P < 0.05), but there were no significant differences be-
tween T4 and T2 (P > 0.05). The results of blood gas
analysis were significantly improved at 2 hours of
NPPV treatment (T3) compared with pretreatment
(T1) (P < 0.05). Positive correlation was found between
PaCO2 changes (T3 vs T1) and AVRIS changes (T2 vs
T1) before and after NPPV treatment (r2 = 0.665,
P < 0.05) (Figure 3). The NPPV treatment was stopped
for four patients whose condition was not improved or
even deteriorated as shown by blood gas analysis at two
hours after treatment. The total AVRIS changes in theNPPV treatment and after NPPV treatment
VPG RG AVRIS QLDD
.41 ± 1.12 0.79 ± 0.29 18.13 ± 3.67 0.34 ± 37.44
.46 ± 0.67 0.83 ± 0.31 13.16 ± 3.67 4.11 ± 32.61
.75 ± 0.51 0.75 ± 0.31 15.25 ± 1.26 2.89 ± 35.45
.98 0.29 6.18 4.33
0.01 a,b,c 0.75 <0.01 a,b,c 0.02 a, b
treatment, T4 = at 15 min after the end of NPPV treatment, VC Score = Score
imal energy frame image, EVPG = Grading of expiratory vibration energy peak,
een the right and left lungs.
Figure 3 Correlation between clinical improvement and VRI image score in AECOPD group. The change of AVRIS (T2 vs T1) is positively
correlated with the changes of PaCO2 (T3 vs T1).
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them had excessive secretions and poor voluntary cough
function. Subsequently, three of them received trachea
cannula and one died. NPPV treatment was continued in
the remaining 32 patients, none of whom received tra-
chea cannula. They were discharged after their condi-
tions were improved (See Table 4).
Discussion
Since a breath sound is highly related to the gas distribu-
tion in the lungs, it can be used to determine the venti-
lation condition at different areas of the lungs [16].
Airway obstruction or stenosis can result in abnormal
function of regional ventilation and a corresponding
change in breath sounds [17]. With the aid of computer,
VRI enables the lung sounds to be objectively recorded,
quantified and imaged in two dimensions so that dy-
namic changes in ventilation can be “visualized”. As anTable 4 Clinical observation indices of AECOPD patients at di
Group HR (/Min.) MAP (mmHg) RR (/Min.) SPO2 (%) VAS
T1 109.31 ± 14.62 99.63 ± 10.36 36.35 ± 7.92 94.51 ± 2.52 6.68 ± 0
T2 98.24 ±7.13 98.45 ± 9.72 25.21 ± 6.43 94.23 ± 2.13 4.31 ± 0
T3 97.95 ± 8.52 98.11 ± 10.63 23.24 ± 8.21 94.78 ± 2.41 3.98 ± 0
T4 99.65 ± 8.72 99.23 ± 11.37 26.54 ± 9.16 94.35 ± 2.31 4.82 ± 0
F 4.66 0.01 2.25 0.05 5.35
P 0.016 a,c 0.99 0.12 a c 0.95 <0.01 a,
Post hoc: a P< 0.05 (T2 vs. T1); b P< 0.05 (T4 vs. T2), c P< 0.05 (T4 vs.T1), d P< 0.05 (T
Abbreviations: TP = Time point, T1 = Before NPPV treatment, T2 = at 15 min of NPP
of NPPV treatment, HR = heart rate, MAP = mean arterial pressure, RR = respiratory
AMUS = scale for accessory muscle use, PH = Potential Of Hydrogen, PCO2 = partiaeffective ventilation support method, NPPV can improve
the ventilatory function of AECOPD patients. Therefore,
it is possible for VRI to quickly display the changes of a
patient’s ventilatory function over the NPPV treatment.
This hypothesis was confirmed by the present study,
in which, the features of VRI in patients with AECOPD
were obviously different from those in healthy volun-
teers. Distinct decline in total AVRIS was found at
15 min of NPPV treatment (T2) compared with T1, and
was correlated to the improvement of patients’ clinical
indexes (such as PCO2). Blood gas analysis (two hours
later) is considered more as the “gold standard” for
evaluating the initial therapeutic effect. Positive correl-
ation was found between changes in PaCO2 (T3 vs T1)
and changes in AVRIS (T2 vs T1). Therefore, VRI may
be also an effective method for evaluating the ITE. In
addition, significant changes can be noted earlier in VRI
image (15 minutes later, T2) than with blood gas analysisfferent time points
AMUS PH PCO2 (mmHg) PO2/FiO2 HCO3 mmol/l
.79 4.21 ± 0.83 7.27 ± 0.09 87.35 ± 9.61 243 ± 32 35 ± 6
.56 3.12 ± 0.48
.84 3.03 ± 0.52 7.33 ± 0.12 71.31 ± 7.53 257 ± 24 34 ± 4
.82 3.64 ± 0.68
2.36 0.69 6.36 1.20 0.53
c 0.11 a, c 0.41 0.02 d 0.26 0.61
3 vs.T1).
V treatment, T3 = at 2 hours of NPPV treatment, T4 = at 15 min after the end
rate, SPO2 = Pulse oxygen saturation, VAS = visual analogue scale grading,
l pressure of carbon dioxide.
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at 15 minutes of NPPV (such as HR, RR, VAS score and
SAMU scores) were also significantly lowered than base-
line (T1), those were more readily affected by other fac-
tors and were with a subjective, patient-perceived nature
compared with VRI.
NPPV treatment was only a ventilation-supporting ap-
proach. When NPPV treatment was paused, the patients’
clinical condition should have resumed what it was be-
fore the treatment unless the primary disease was cured.
In our study, no obvious change were found in the clin-
ical indexes at T4 vs T2, but there was a distinct differ-
ence in abnormal VRI image score (T4 vs T2) among
the patients. From another point of view, this suggested
that VRI could quickly reflect the effects of NPPV treat-
ment on patients’ ventilatory function and was more
sensitive than commonly used clinical indexes. We fur-
ther found that VRI changes were in accordance with
the physiological changes that reflected the ventilatory
function during the NPPV treatment.
After NPPV treatment, the VRI images of 14 healthy
volunteers showed a low and flat expiration (LFE), name-
ly, the vibration energy of the expiration phase appeared
low and flat. It may be caused by a positive end-expiratory
pressure (PEEP), which generates a physiological effect
similar to intrinsic PEEP during expiration. Therefore,
the limited expiratory airflow was displayed in the VEC
as a low and flat expiratory phase. Intrinsic PEEP is com-
monly found in AECOPD patients and is considered as
the primary cause of expiration airflow limitation, inspir-
ation load increase and respiration failure [18]. An im-
portant mechanism by which NPPV improves ventilatory
function is to confront intrinsic PEEP with a proper level
of external PEEP [19]. In this research, only a few pa-
tients obtained improved LFE in VRI images. The pos-
sible reason is that the relative low PEEP (5 cmH2O)
could not completely counteract the intrinsic PEEP of
AECOPD patients at the initial stage of NPPV treatment.
As found by Shaul Lev, et al, a VRI examination could
monitor the physiological influences on patients with
mechanical ventilation by different PEEP levels [20].
MEF can provide more detailed information about re-
spiratory sounds as it reflects air distribution at the peak
of air vibration in the lung. Abnormal MEF shapes reflect
air distribution of regional airway obstruction or stenosis
[21]. The vortex flow and partial dysfunction of ventila-
tion in COPD patients were proved by dynamic magnetic
resonance imaging with He-3 absorption, accounting for
the unsmooth edge of MEF image in AECOPD patients
[22]. Previous researches showed that there existed pul-
monary alveoli with different time constants. The filling
velocity of “quick” and “slow” pulmonary alveoli varied
during normal breathing [23]. The initial high-speed air-
flow generated by a positive pressure may reach thecentral respiratory tract rapidly during NPPV treatment.
Therefore, it will take more time for the airflow to be
uniformly distributed in “quick” and “slow” pulmonary
alveoli. In our research, 11 patients had improved MEF
images after NPPV treatment, similar to the MEF charac-
teristics in patients with asthma after absorption of bron-
chodilator [15]. Because structural improvements in the
AECOPD lungs cannot be achieved in a short time, the
dynamic images of the patients tended to restore to their
initial pretreatment conditions once the NPPV treatment
was terminated. Dellinger et al found that a VRI examin-
ation can estimate the influences of different mechanical
ventilation modes on the energy distribution in patients
who received the invasive mechanical ventilation [24]. In
this study, we also observed the influences of NPPV on
the vibration energy distribution in the bilateral lungs.
QLD values of the left and right lungs were approxi-
mately equal in normal subjects. The QLD values of
the left and right lungs in AECOPD patients, however,
were found to be about 10% deviated from each other.
After NPPV treatment, the QLD values of the left and
right lungs were close to those in normal subjects (4%),
suggesting that NPPV therapy can improve the air dis-
tribution in the lungs, resulting in more uniform air dis-
tribution in the bilateral lungs.
The breathing airflow of a normal subject produces
continuous vibration when passing through an uninter-
rupted branching airway. Since AECOPD patients usu-
ally suffer inflammation and sputum blocking, their
uneven airflow resistance will result in discontinuous vi-
bration energy in both time and space. Such discontinu-
ity is reflected by unsmooth, sagging and step of the
VEC, or by image jumping, lagging and inverse domin-
ance in the dynamic vibration energy image [25]. The
mechanism by which NPPV improves ventilatory func-
tion also involves the positive pressure ventilation which
can overcome the airway resistance and increase the al-
veolar ventilation [19]. After NPPV treatment, AECOPD
patients tended to generate uniform airway resistance
against the breathing airflow and relatively continuous
vibration energy. Therefore, their VEC and dynamic VRI
image improved.
After NPPV treatment, a few healthy volunteers showed
abnormities in the VRI image, such as desynchrony and
unequal heights of EVP curves and an unsmooth MEF
edge. This might be caused by desynchronization of the
lung ventilation during NPPV. AECOPD patients may
also suffer from desynchronization during NPPV; but in
most cases, this may be hidden by the efficacy of NPPV
therapy. The AVRIS increased rather than decreased in 4
patients after NPPV treatment and their clinical condi-
tions did not improved, which might also be caused by
the serious desynchronization. All the 4 patients had ex-
cessive secretions in the airway and serious pathological
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sufficient to improve the ventilatory function without a
prior effectively anti-infective therapy or expectoration.
This finding is consistent with our clinical experience
that NPPV therapy, as recommended by guidebooks,
should be avoided for patients with too much sputum.
The improved ventilatory function can be reflected by
decline of the total AVRIS, which is significantly corre-
lated with the decline of PCO2. However, it is noticeable
that a decrease in the scores of sub-items does not ne-
cessarily suggest an improved ventilatory function but
sometimes indicates a deteriorated ventilatory function.
For instance, the inspiratory steep which appeared in the
VEC of 11 AECOPD patients after NPPV treatment
might only be related to the high-speed airflow of initial
inspiration during positive pressure ventilation. In addi-
tion, another three AECOPD patients showed no dry or
moist rales over lung auscultation and VRI examination
before NPPV treatment. However, their dry and moist
rales were found after NPPV treatment, which might be
related to their amplified breath sound or to their im-
proved ventilatory function. Therefore, in an AECOPD
patient, attention should be paid not only to the changes
in total or partial AVRIS but also to the clinical signifi-
cance of each AVRIS component. As a result, the func-
tional changes in ventilation reflected by the changes in
AVRIS should be judged comprehensively. Further stud-
ies are needed to clarify this finding.
Several limitations of the present study should be
acknowledged. Firstly, this is a single-center study with a
relatively small sample size. Future studies with multi-
center collaborations are warranted to verify our find-
ings. Secondly, the VRI findings in this study correlated
with clinical changes in HR and VAS (p < 0.05), as well
as respiratory rate and AMUS (not significant). These
observations did not support a clear-cut superiority of
VRI over these indices. Nevertheless, our study showed
that VRI can be at least a supplementary tool for earlier
evaluation of the initial therapeutic effects in NPPV.
Conclusions
In summary, VRI may quickly display the functional
changes during NPPV treatment, and is highly corre-
lated with the commonly-used clinical indices (such as
PaCO2). In addition, VRI changes were in accordance
with the physiological changes that reflected the ventila-
tory function during the NPPV treatment. Therefore,
VRI is a promising noninvasive tool for evaluating the
initial therapeutic effects of NPPV in AECOPD patients
and predicting the success of NPPV in the early stage.
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